The QualityStocks Daily Tuesday, July 3rd, 2018

Today's Top 3 Investment Newsletters

BUYINS.NET (TGC) +73.71%

MarketBeat (AHI) +50.00%

StocksToBuyNow (PRVCF) +44.96%

The QualityStocks Daily Stock List

U.S. Stem Cell, Inc. (USRM)

InvestorsHub, MarketWatch, TradingView, and Money Morning reported on U.S. Stem Cell, Inc. (USRM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

U.S. Stem Cell, Inc. is a developing business in the regenerative medicine/cellular therapy industry. The Company is a developer of novel autologous cell therapies, and a provider of physician-based stem cell therapies to human and animal patients. U.S. Stem Cell is based in Sunrise, Florida. The Company formerly went by the name Bioheart, Inc. It changed its name to U.S. Stem Cell, Inc. in October of 2015.

The Company has three operating divisions: US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic. U.S. Stem Cell is a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions. Its concentration is on the discovery, development, and commercialization of cell-based therapeutics that prevent, treat, or cure disease through repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.

U.S. Stem Cell’s business includes the development of proprietary cell therapy products and revenue generating physician and patient based regenerative medicine/cell therapy training services. In addition, the Company’s business includes cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic.

U.S. Stem Cell’s lead product candidate is MyoCell®. This is a muscle stem cell therapy intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the Food and Drug Administration (FDA) to commence human clinical trials. The intention of MyoCell SDF-1 is to be an improvement to MyoCell.

U.S. Stem Cell has developed a strategic alliance with Advanced Stem Cell Rx (ASC). This includes the development of autologous stem cell treatment centers across the United States. ASC is a U.S. based provider of regenerative medicine programs.

U.S. Stem Cell announced in January 2018 that it reached an important milestone of 10,000 kit sales of its proprietary Adipocell™ product. This is a direct result of its relationships with 287 clinics in the United States and 700-plus physicians worldwide offering the Company’s proprietary stem cell products and services.

Last month, U.S. Stem Cell announced Renewing Our Heroes - a charitable health initiative created to provide first responders and other civil service personnel with access to alternative medical care they would otherwise be unable to obtain - will now offer the Company’s stem cell procedures and protocols to its recipients following injuries and conditions that occur in the line of duty.

Mr. Mike Tomas, U.S. Stem Cell’s President and Chief Executive Officer, said, "Expansion of our stem cell protocol into the line of service for our first responders means we are starting to reach more and more Americans who otherwise would never have access to this incredible regenerative therapy. It is an honor for our organization to know the true heroes of our country can now have access to this standard of care."

U.S. Stem Cell, Inc. (USRM), closed Tuesday's trading session at $0.02968, up 5.62%, on 761,599 volume with 22 trades. The average volume for the last 60 days is 2,422,156 and the stock's 52-week low/high is $0.016/$0.088.

chart

Orbital Tracking Corp. (TRKK)

Beacon Equity Research, SuperStockTips, Penny Stock Finder, Penny Stock Craze, MicroCapDaily, OTCMagic, Stock Commander, Penny Stock General, Fast Money Alerts, Stock Shock and Awe, Stock Preacher, SmallCap Network, InvestorSoup, and Shiznit Stocks reported earlier on Orbital Tracking Corp. (TRKK), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Orbital Tracking Corp. provides satellite-based tracking, services, and mobile voice and data communications services globally, via satellite, to commercial and government users. In February 2015, the Company completed a reverse merger and a subsequent $1.1 million equity capital raise. This created Orbital Tracking Corp., a publically listed organization including the operations of Global Telesat Communications Ltd., a UK corporation (GTCL). Orbital Tracking has its head office in Aventura, Florida.

Orbital Tracking (as a newly combined entity) launched as a fully operational Mobile Satellite Solutions (MSS) business. It specializes in services related to the Globalstar satellite constellation. This includes ground station construction, simplex tracking services, as well as satellite telecommunications voice airtime.

Orbital Tracking operates different e-commerce retail and tracking sites where users internationally can buy satellite hardware and track assets in real-time on mobile devices or personal computers (PCs).

The Company’s subsidiaries, U.S.-based Orbital Satcom Corp. and European Union (EU)-based Global Telesat Communications Ltd., provide around the world distribution of a wide array of portable satellite voice, data, and tracking solutions.

Global Telesat Communications (GTC) is a supplier of mobile voice and data communications services through satellite. GTC provides equipment and airtime for use on all the major satellite networks. This includes Globalstar, Inmarsat, Iridium, and Thuraya, allowing users in remote locations to make phone calls, connect to the internet, and track assets or personnel anywhere around the world.

In May, Orbital Tracking reported financial results for the three months ended March 31, 2018. Consolidated Revenues reached record levels, versus the same period in the prior year, increasing $285,606 or 20.7 percent to $1,667,938, versus $1,382,332 for the quarter ended March 31, 2017.

Orbital Tracking recorded a Net Loss before Income Tax of roughly $145,458 for the three months ended March 31, 2018 versus a loss of $219,262, for the three months ended March 31, 2017.

In Q1 2018, Orbital Tracking further expanded its reach into new markets through the opening of its first e-commerce storefront in Australia. Notable orders it received during the quarter in terms of Sales Revenue included the supply of satellite terminals and airtime for use by a disaster preparedness organization and annual renewal of the UK’s Forestry Commission’s 750+ SPOT Gen3 messaging plans.

Orbital Tracking Corp. (TRKK), closed Tuesday's trading session at $1.68, up 12.00%, on 457 volume with 4 trades. The average volume for the last 60 days is 805 and the stock's 52-week low/high is $1.365/$4.485.

chart

Thunder Mountain Gold, Inc. (THMG)

FeedBlitz, Zacks, and MarketWatch reported on Thunder Mountain Gold, Inc. (THMG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Thunder Mountain Gold, Inc. is a junior gold exploration company listed on the OTCQB. The Company owns interests in many U.S. precious metals projects. Its principal asset is The South Mountain Project. The South Mountain Project is on private and patented land in southern Idaho, just north of the Nevada border. Established in 1935, Thunder Mountain Gold is based in Boise, Idaho.

The Company also has its Trout Creek Project. The Trout Creek target is in the Reese River Valley area south of Battle Mountain, Lander County, Nevada. This is a grass roots gold target in the Eureka-Battle Mountain trend of central Nevada, now under Joint Exploration Agreement with Newmont USA Limited. This target comprises 60 unpatented lode mining claims.

Thunder Mountain Gold’s other projects include Clover Mountain. The Company controls 40 unpatented lode mining claims encompassing roughly 800 acres, near Clover Mountain in Owyhee County, Idaho. Furthermore, its West Tonopah Property consists of 8 unpatented lode mining claims totaling 160 acres in the Tonopah Mining District, Esmeralda County, Nevada.

Thunder Mountain Gold owns 100 percent of the above-mentioned South Mountain Mine. This mine has a land package consisting of roughly 1,200 acres of mostly private land - both owned outright and leased. In 2009, a new gold discovery was revealed during fieldwork at South Mountain. The Company’s plan of operation for this, subject to business conditions, is to continue to advance the development at the South Mountain Project.

The flagship South Mountain Project remains Thunder Mountain Gold’s focus. The primary metals at South Mountain are silver, zinc, lead, copper, and gold.

In June, Thunder Mountain Gold announced that it filed a new National Instrument 43-101 (NI 43-101) Technical Report, which included a new mineral resource estimate on the South Mountain Project. The Technical Report has an effective date of April 7, 2018. The most recent Thunder Mountain Gold drilling program was successful in defining the geometry and confirming the grades of the DMEA and Texas massive sulfide zones.

Hard Rock Consulting, LLC (HRC) of Lakewood, Colorado completed the Technical Report for the Company`s South Mountain Project. HRC concludes that major potential exists to increase the known mineral resource with additional drilling, and to upgrade existing mineral resource classifications with additional infill drilling.

Thunder Mountain Gold, Inc. (THMG), closed Tuesday's trading session at $0.15145, down 15.86%, on 200 volume with 1 trade. The average volume for the last 60 days is 10,220 and the stock's 52-week low/high is $0.075/$0.30.

chart

Amarantus Bioscience Holdings, Inc. (AMBS)

Stockopedia, Nasdaq.com, Stockhouse, 4-Traders, Zacks, Streetwise Reports, InvestorsHub, and Insider Financial reported on Amarantus Bioscience Holdings, Inc. (AMBS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Formed in 2008, Amarantus Bioscience Holdings, Inc. is JLABS-alumnus biotechnology holding company. It is developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies through its subsidiaries. The Company’s wholly-owned subsidiaries include Elto Pharma, Inc; Cutanogen Corporation, and MANF Therapeutics. Amarantus Bioscience Holdings is based in New York, New York.

Amarantus Bioscience also owns about 79.25 million shares of Avant Diagnostics, Inc. (AVDX) via the sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc. that took place in May 2016.

Amarantus Bioscience is centering on developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The Company’s lead therapeutic program is eltoprazine. This is a Phase 2b-ready small molecule indicated for the treatment of Levodopa-induced dyskinesia - one of the most difficult problems facing patients with Parkinson’s disease.

Elto Pharma has development rights to eltoprazine. In addition, eltoprazine is undergoing evaluation for the treatment of adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression.

The Company’s diagnostics division is Amarantus Diagnostics. Its lead diagnostic product is LymPro Test®. This is a blood-based assay to diagnose Alzheimer’s disease. LymPro Test® is approved for investigational use only to be used in biotechnology and pharmaceutical clinical trials.

Amarantus Diagnostics is also developing MSPrecise®. This is a proprietary, next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple sclerosis (RRMS) at first clinical presentation.

Amarantus Bioscience’s subsidiary MANF Therapeutics owns key intellectual property (IP) rights and licenses from many prominent universities related to the development of the therapeutic protein called mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics is developing MANF-based products as treatments for brain and ophthalmic disorders.

Also, Amarantus Bioscience acquired the rights to the Engineered Skin Substitute program. This is a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by subsidiary Cutanogen Corporation.

Recently, Amarantus Bioscience announced that based upon its review of the clinical data from a German-based clinical study led by Leipzig University's Dr. Thomas Arendt, it exercised its Exclusive Option with Leipzig to negotiate license rights to Alzheimer's blood diagnostic "LymPro Test 2.0," that compares traditional LymPro Test results with those of amyloid PET imaging for the diagnosis of Alzheimer's disease.

Amarantus Bioscience and Leipzig University agreed to broaden the scope of license negotiations to include additional key markers collected during the clinical study. This includes CSF-tau.

Amarantus Bioscience recently received an independent third-party valuation report that valued the Parkinson's disease levodopa-induced dyskinesia (PD-LID) indication for Eltoprazine in the United States and Europe at $316 million. Company management has outlined two distinct paths for Elto Pharma to get as much value for the Eltoprazine asset for Amarantus Bioscience as possible.

One path is standalone private funding followed by a U.S. or Hong Kong-based IPO. The second path may be a business combination with an established clinical-stage biopharmaceutical company with strong management and a first-rate pipeline in which Amarantus Bioscience could become a major shareholder. Amarantus Bioscience expects to make a final determination on the capital formation plan for Elto Pharma this summer.

Amarantus Bioscience Holdings, Inc. (AMBS), closed Tuesday's trading session at $0.0368, even for the day, on 309,270 volume with 18 trades. The average volume for the last 60 days is 965,862 and the stock's 52-week low/high is $0.01/$0.2085.

chart

CV Sciences, Inc. (CVSI)

OTCtipReporter, Penny Picks, PennyStockScholar, Profitable Trader Authority, Promotion Stock Secrets, Wealth Insider Alert, Market Intelligence Center Alert, StreetAuthority Daily, Wall Street Mover, Damn Good Penny Picks, and Stock Commander reported previously on CV Sciences, Inc. (CVSI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

CV Sciences, Inc. centers on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD). A life science company, it operates two divisions - Pharmaceuticals and Consumer Products. These divisions are supported by its medical and scientific advisory board, and state‐of‐the art production facilities. CV Sciences lists on the OTCQB.

The Company previously went by the name CannaVEST Corp. It changed its name to CV Sciences, Inc. in January 2016. CV Sciences has main offices and facilities in San Diego, California and Las Vegas, Nevada.

The Company’s Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Each consumer products brand is backed by a formal safety review, an increasing body of case reports, and physician’s recommendations. Furthermore, CV Sciences manufactures, markets, and sells plant-based CBD products under the PlusCBD brand. This is for a variety of market sectors. These include nutraceutical, beauty care, specialty foods, and also vape.

CV Sciences’ Pharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine. It is pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications using cannabidiol as the active pharmaceutical ingredient. The Company has attained promising preclinical results in the development of cannabinoid medicines for the treatment of an array of medical conditions.

CV Sciences acquired CanX, Inc. in December 2015. CanX is a Pre-Clinical drug development company. It is concentrating on significant unmet medical needs. CanX’s initial drug candidate is CVSI-007. CVSI-007 chewing gum combines CBD and Nicotine. It is patent pending. CVSI-007 is a proprietary chewing gum. It combines synthetic CBD and nicotine to effectively treat smokeless tobacco addiction.

CV Sciences drug development efforts include pursuing synthetic-based Cannabidiol (CBD) drug candidates in areas that have the potential to provide important improvements in therapeutic patient treatments with significant addressable markets.

The Company’s consumer products division has its Purified Liquids™ (high quality, premium CBD vape e-liquids). The launch of this brand targets the increasing vape industry. Purified Liquids™ is made from 99.9 percent CBD from hemp-derived crystals. It contains 0 percent THC.

This past September, CV Sciences commented on the latest research citing Cannabidiol in lessening the risk of Post-Traumatic Stress Disorder (PTSD). The Company highlighted another study identifying additional therapeutic opportunities of cannabidiol (CBD) that include the potential to prevent PTSD.

Researchers at the Federal University of Parana, Santa Catarina, and the University of Sao Paulo, have preclinical evidence that when given immediately after a fearful event, CBD can considerably decrease the conditioned fear expression and fear generalization and the relative resistance to extinction of the fear memory. These findings have important implications for the possible role of CBD in reducing PTSD.

CV Sciences is scheduled to host a conference call to discuss its Q3 2017 results at 1:15 pm PT/4:15pm ET on Wednesday, November 8, 2017. The Company’s Chief Financial Officer (CFO), Mr. Joseph Dowling, will lead the call to provide an operational and financial summary of CV Sciences’ Q3 of 2017.

CV Sciences, Inc. (CVSI), closed Tuesday's trading session at $1.63, up 1.88%, on 439,342 volume with 467 trades. The average volume for the last 60 days is 2,092,174 and the stock's 52-week low/high is $0.136/$2.78.

chart

Molori Energy, Inc. (MOLOF)

Streetwise Reports, InvestorsHub, Stockhouse, and MarketWatch reported on Molori Energy, Inc. (MOLOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

An oil and gas production company, Molori Energy, Inc. has present operations in the Texas Panhandle West Field. The Company’s operating team, which is based in Borger, Texas, has wide-ranging experience in the oil and gas industry in the Texas Panhandle. Molori Energy's business model is to deliver sustainable growth in shareholder value through concentrating on exploiting its existing reserves, commercializing and developing discoveries, and pursuing selective acquisitions. Molori Energy is based in Vancouver, British Columbia.

Currently, the Company owns a 25 percent working interest (WI) in certain leases situated in the bifurcated Texas panhandle, operated by its Texas-based partner Ponderosa Energy, LLC. Molori Energy has 165 producing (PDP) wells as well as an inventory of roughly 202 non-producing wells (PDNP) for a total of 367 wells. The Company is working to RTP (Return To Production) the PDNP wells through performing simple re-works or re-completions.

These assets include low-decline, PDP weighted reserves mainly in the West Panhandle Field of the Hugoton Basin of Texas. These assets are about 50 percent oil and 50 percent liquid rich gas (HIGH BTU premium gas) principally situated in Carson, Gray, and Hutchinson Counties of District 10.

Molori Energy’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to produce steady cash flows. Over 60 wells have been reactivated so far. These are producing from the prolific Brown Dolomite formation.

Molori Energy and Ponderosa Energy have identified a development opportunity in the Red Cave formation. This formation is common throughout its leases at a shallower depth of 2,100’ to 2,300’. Improved fracing technologies and completion techniques have shown the Red Cave to be an economic development target.

Last month, Molori Energy announced the signing of a definitive agreement to purchase an additional 25 percent WI in certain oil and gas leases from its Texas-based operating partner, Ponderosa Energy. This latest acquisition, combined with the 25 percent interest the Company currently has in these same leases, will bring Molori Energy's overall interest to 50 percent.

In addition, last month, Molori Energy announced the signing of a definitive agreement to secure a 75 percent WI in certain oil and gas leases, known formally as the "Red Cave Leases" in District 10, Texas. This acquisition of these leases, encompassing 11,000 acres with access to Red Cave, and with access to other formations, is an important milestone of Phase 1 of Molori Energy's development plan.

Mr. Joel Dumaresq, Molori Energy’s Chief Executive Officer, said, "The acquisition of this expansive land package is the result of many months of work, evaluation and negotiation. With the recent commercial success of the M1 Well on our existing acreage, we have decided to focus our exploration efforts and capital on this prospective new acreage as its sheer size provides us with the greatest opportunity to add significantly to our reserves."

Molori Energy, Inc. (MOLOF), closed Tuesday's trading session at $0.147, up 3.25%, on 10,800 volume with 7 trades. The average volume for the last 60 days is 54,230 and the stock's 52-week low/high is $0.1182/$0.5066.

chart

Avalon Globocare Corp. (AVCO)

OTC Markets, InvestorsHub, and TradingView reported on Avalon Globocare Corp. (AVCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Avalon Globocare Corp. provides healthcare services in the U.S. and China. The Company operates via its main platforms: Avalon Cell and Avalon Rehabilitation. Avalon’s management draws on their abundance of experience and extensive networks in the biotechnology industry, health care management, as well as academia. Avalon Globocare is based in Freehold, New Jersey. The Company lists on the OTC Markets’ OTCQB.

Avalon Globocare is a premier healthcare management provider and biotechnology developer. Avalon’s commitment is to integrating and managing worldwide healthcare resources. In addition, Avalon, by way of its subsidiary “Avalon RT9 Properties, LLC”, engages in the acquirement and management of healthcare facilities.

The Company’s “Avalon Cell” platform concentrates on cell-based therapies and technologies. Its focus is in the field of in vitro diagnostics, regenerative medicine, and also cancer immunotherapy. Avalon Cell focuses on transformative and high-impact cell-based bio-technology opportunities in the U.S. and China. It then fast tracks these to clinical development and commercialization internationally.

The “Avalon Rehabilitation” platform is a turnkey, complete suite of rehabilitation services. These services include PT, OT, robotic engineering, cybernectics, and clinical nutrition. Regarding Avalon Globocare’s healthcare facility, it presently includes healthcare property management services, chiefly through acquiring and managing healthcare real estate facilities, stem cell banks, and a CAP-certified laboratory, which will complement the Company’s existing platforms.

Last week, Avalon Globocare announced that its majority-owned subsidiary, GenExosome Technologies, Inc., acquired 100 percent of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. At the same time, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, Chief Executive Officer of GenExosome Beijing, whereby GenExosome acquired all assets, including all intellectual property (IP), patents and patent applications held by Dr. Zhou regarding the business of researching, developing, and commercializing exosome technologies.

This week, Avalon Globocare announced that it appointed former Congressman, Mr. Billy Tauzin, to the Company’s Board of Directors. Congressman Tauzin has a long and distinguished 36-year elective career. It culminated in chairing the Energy and Commerce Committee (ECC) in the U.S. House of Representatives. The ECC supervises food and drug safety, public health and research, telecommunications, consumer protection, environmental quality, energy policy, and interstate and foreign commerce among others.

Avalon Globocare Corp. (AVCO), closed Tuesday's trading session at $2.71, up 2.26%, on 485 volume with 3 trades. The average volume for the last 60 days is 4,304 and the stock's 52-week low/high is $0.51/$4.60.

chart

Texas Mineral Resources Corp. (TMRC)

OTC Markets, InvestorsHub, Marketwired, and Stockrow reported on Texas Mineral Resources Corp. (TMRC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Headquartered in Sierra Blanca, Texas, Texas Mineral Resources Corp. is an exploration company. It is targeting the heavy rare earths and an array of other high-value elements and industrial minerals. The Company’s emphasis is exploring and, if warranted, developing its Round Top heavy rare earth and industrial minerals project in Hudspeth County, Texas, 85 miles east of El Paso.

Texas Mineral Resources lists on the OTC Markets Group’s OTCQB. The Company previously went by the name Texas Rare Earth Resources Corp. It changed its name to Texas Mineral Resources Corp. in March of 2016.

Furthermore, Texas Mineral Resources’ plan is to develop alternative sources of strategic minerals via the processing of coal waste and other related materials. The Company’s flagship property, Round Top Mountain, is near Sierra Blanca in Hudspeth County.

Texas Mineral Resources holds 19-year renewable leases from the State of Texas on 950 acres covering Round Top and additional prospecting permits on adjacent areas encompassing an additional 9,345 acres. At present, the Company is concentrating on the exploration and development of rare earth elements at Round Top.

Round Top is one of four principal rhyolite bodies, an igneous volcanic rock, making up the group of mountains called The Sierra Blanca. The PEA has been completed based on the measured, indicated and inferred Resource Estimate Technical Report filed on December 20, 2013 by Texas Rare Earth Resources.

The PEA and resource estimate was prepared by Gustavson Associates of Lakewood, Colorado. The resource incorporated into the present mine plan totals 525.4 million kg of rare earth oxide (REO), with an average grade of 634 ppm total rare earth oxides (TREO). Of the TREO, roughly 72 percent consist of heavy rare earth oxides plus Yttrium.

In 2017, Texas Mineral Resources added a new strategic line of business with the establishment of a subsidiary called American Mineral Reclamation LLC. The formation of this subsidiary is in response to the increasing number of opportunities that the Company was presented because of work undertaken with partners that resulted in winning grants from the Department of Defense (Defense Logistics Agency) and the Department of Energy.

Recently, Texas Mineral Resources announced it signed a Memorandum of Understanding (MOU) with an investor group led by a number of mining industry executives for a $6 million equity funding of a newly created Round Top Minerals entity.

With this MOU, the investor group is granted up to a 180 day due diligence period to complete the financing. The investor group would own 49 percent of the Round Top Minerals entity with Texas Mineral Resources shareholders owning 51 percent.

Texas Mineral Resources Corp. (TMRC), closed Tuesday's trading session at $0.23, up 7.48%, on 20,650 volume with 8 trades. The average volume for the last 60 days is 27,976 and the stock's 52-week low/high is $0.13/$0.25.

chart

Validian Corp. (VLDI)

Value Penny Stocks, Epic Stock Picks, Hot Stock Profits, StockMarketIntel, TopPennyStockMovers, Profit Sensation, Stock News Now, Damn Good Penny Picks, Penny Picks, PREPUMP STOCKS, Penny Stock Newsletter, Pumps and Dumps, PennyStocks24, and OTC Stock Review reported previously on Validian Corp. (VLDI), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Validian Corp. provides software products for public and private enterprises. In essence, the Company is a top innovator in cyber-security technology. Validian develops and markets solutions to protect against the threats of today's digital world. Validian is first-to-market to provide secure storage, access, and transfer of digital information on wired, wireless, or mobile networks over the Internet. Listed on the OTC Markets Group’s OTCQB, Validian is headquartered in Ottawa, Ontario.

The Company’s technology enables the next generation of secure Cloud Computing, Cloud Storage, Distributed Computing and Web Application and WebPortal Access and Usage for desktop and laptop computers, servers, tablets, and Smartphones. Validian’s products include Validian Protect, which embeds its technology into any application.

Validian provides solutions that can undergo customization to the client's business process to ensure end-to-end authenticity, integrity, and custody of high value digital assets. Validian’s corporate mission is to deliver innovative information protection solutions that help government agencies, enterprises, and individuals in lessening the impact of theft, disclosure, non-compliance, or malicious tampering with digital assets.

The Company has extended its core technology, ValidianProtect. It is now the first cyber security technology to cover and seamlessly protect the Complete Life Cycle of Data with secure access, retrieval, transfer, receipt, storage, and usage of digital information on all devices, operating systems, and technology platforms.

Validian redesigned its ValidianProtect technology to include a group of downloadable, re-usable, feature modules. These make it possible for a programmer to quickly and easily add any combination of a substantial number of pre-built, commonly used functions and first-to-market differentiating features to or from any application, thus saving them numerous man-years of previously extra development time.

In August 2017, Validian announced that it recently completed version 3.3 of its inventive cybersecurity technology. This technology seamlessly protects the Complete Life Cycle of Data on all major technology platforms, operating systems, and devices. This completion consisted of minor modifications in addition to the migration and upgrades already completed to Microsoft Windows 10 and the Azure Cloud platform, as well as to recent versions of Google Android, Apple OS and iOS, and to Red Hat Linux.

This week, Validian confirmed that some of the large corporations now in talks with Validian concerning strategic partnership agreements are interested in utilizing the Company’s technology to secure and enhance automotive connectivity and communications. This includes vehicle to vehicle communications.

Validian Corp. (VLDI), closed Tuesday's trading session at $0.00855, up 4.27%, on 449,362 volume with 7 trades. The average volume for the last 60 days is 1,550,869 and the stock's 52-week low/high is $0.0046/$0.027.

chart

SolGold plc (SLGGF)

Zacks, Barchart, Amigo Bulls, Morningstar, MarketWatch, Stockhouse, The Street, InvestorPlace, 4-Traders, OTC Markets, Wallet Investor, GuruFocus, TradingView, Stockwatch, and Stockwolf reported on SolGold plc (SLGGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

SolGold plc mainly explores for gold, copper, and silver deposits. The Company’s emphasis is on the riches of the North Andean Copper Belt in Ecuador. Cascabel is SolGold’s flagship project. In addition, SolGold is exploring a further 3,200km² of new ground within Ecuador. SolGold has its corporate office in Brisbane, Queensland, Australia. It also has a London corporate office and a Quito corporate office.

Fundamentally, SolGold is a copper gold exploration and future development company that has assets in Ecuador, the Solomon Islands and Australia. The Company’s principal goal is to discover and define world‐class copper‐gold deposits in Ecuador.

SolGold’s flagship Cascabel is the most advanced project in Northern Ecuador. Cascabel is a tier-one world class project. The Cascabel Project is a porphyry copper- gold deposit. Cascabel is situated in the Imbabura province of northwest Ecuador.

The Company has drill tested 5 of 15 copper-gold targets delineated in the 50 km2 tenement with a concentration on Alpala.  The remainder of the targets, including Aguinaga, Trivinio, Moran, Parambas and Tandayama-America are scheduled for testing this year following completion of ground magnetic modeling and Spartan Orion deep IP surveys.

This past May, SolGold announced new high-grade copper and gold mineralization discovered within Ecuador's richly copper-endowed southern Jurassic Porphyry Corridor. SolGold’s Board provided an update on exploration at its 100 percent owned La Hueca, Porvenir and Timbara Projects, in Southern Ecuador.  These prospects are held in the 100 percent owned subsidiaries Green Rock Resources and Cruz Del Sol S.A.

Selected highlights include two new copper targets discovered on the western side of the La Hueca Project.  Channel chip sampling returned 17.3m @ 3.87% Cu, 0.46 g/t Au (including 6m @ 9.39% Cu, 0.98 g/t Au).

Furthermore, new mineralized outcrops were identified in the Porvenir Project. These are rich in chalcopyrite, chalcocite, covellite, bornite (copper sulphide minerals) and malachite (copper carbonate mineral).

Moreover, last month, SolGold announced continued growth at Alpala and Aguinaga in Ecuador. It also provided an update on exploration at its 100 percent owned Cisne Project in Loja, Southern Ecuador.  This prospect is held in the 100 percent owned subsidiary Green Rock Resources.

First pass stream sediment survey identified a number of areas of strong gold mineralization in the Cisne Loja concessions. Manifold rock chip samples returned gold and silver greater than 1 g/t Au with a best rock sample result of 15.25 g/t Au and 23.6 g/t Ag.

SolGold plc (SLGGF), closed Tuesday's trading session at $0.30, even for the day. The average volume for the last 60 days is 25,296 and the stock's 52-week low/high is $0.276/$0.55.

chart

Grupo TMM, S.A.B. (GTMAY)

Stockhouse, Penny Stock Tweets, Marketbeat, The Street, OTC Markets, Penny Stock Picks, Zacks, CapitalCube, YCharts, Wallet Investor, Amigo Bulls, Last10k, TradingView, Stockwatch, and VentureLine reported on Grupo TMM, S.A.B. (GTMAY), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Grupo TMM, S.A.B. is a Mexican Maritime-management transportation and logistics Company. Grupo TMM operates together with its subsidiaries in Mexico. The Company operates in four segments. These are Maritime, Logistics, Ports and Terminals, and Warehousing. Grupo TMM has its corporate headquarters in Mexico City, Mexico. The Company’s shares trade on the OTC Markets Group’s OTCQB.

As of March 31, 2018, Grupo TMM operated via a fleet of 39 vessels. These include product and chemical tankers, harbor tugs, and different offshore supply vessels.

Grupo TMM provides maritime transportation services. This includes offshore vessels that provide transportation and other services to the Mexican offshore oil industry. The Company also provides tankers that transport petroleum products in Mexican waters; parcel tankers that transport liquid chemical and vegetable oil cargos from and to the U.S. and Mexico; and tugboats that provide towing services at the port of Manzanillo, Mexico.

Additionally, Grupo TMM provides dry bulk carriers, which transport unpackaged commodities, including steel between South America, the Caribbean, and Mexico. It also provides ship repair services by way of two floating drydocks.

The Company also provides port agent services to vessel owners and operators in Mexican ports; and warehousing and bonded warehousing facility management services. Furthermore, it operates the Tuxpan, Tampico, and Acapulco port facilities.

Grupo TMM also offers logistics services; logistics network analysis; logistics information process design; intermodal transport; and supply chain and logistics management. The Company additionally offers product handling and repackaging; local pre-assembly; container maintenance and repair; and inbound and outbound distribution to automobile manufacturers and retailers.

In late April of this year, Grupo TMM reported its financial results for Q1 2018. Consolidated Revenues were $386.8 million, versus $509.3 million in Q1 of 2017.

The 2017 Q1 included the Revenues from TMM Division Maritima (TMMDM) that, as a result of Grupo TMM’s corporate reorganization in December 2017, was deconsolidated from Grupo TMM. Year over year, Ports and Terminals Revenue improved 25.0 percent. Moreover, Warehousing Services Revenues grew 25.2 percent in the 2018 Q1.

Consolidated Operating Profit was $17.8 million versus a loss of $32.9 million in the 2017 Q1.  The 2017 Q1 included the Operating Profit from TMMDM. Year over year, operating results in all divisions improved in Q1 of 2018.

Grupo TMM, S.A.B. (GTMAY), closed Tuesday's trading session at $1.31, up 11.97%, on 34,275 volume with 34 trades. The average volume for the last 60 days is 2,652 and the stock's 52-week low/high is $0.59/$1.47.

chart

Costar Technologies, Inc. (CSTI)

Zacks, OTC Dynamics, Stockflare, Street Insider, Stockwatch, VentureLine, Penny Stock Tweets, Barchart, Amigo Bulls, Stockhouse, Simply Wall St, OTC Markets, InvestorsHub, 4-Traders, Morningstar, Marketbeat, MarketWatch, YCharts, and Infront Analytics reported on Costar Technologies, Inc. (CSTI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Costar Technologies, Inc. develops, designs, manufactures and distributes a range of security solution products. In addition, it develops, designs and distributes industrial vision products to observe repetitive production and assembly lines, thus increasing efficiency by detecting faults in the production process. Costar Technologies has its corporate office in Coppell, Texas.

Costar Technologies consists of four companies. These are CohuHD Costar, Costar Video Systems, Innotech, and IVS Imaging. The Company’s security solution products include surveillance cameras, lenses, digital video recorders, as well as high-speed domes. The combined product portfolio comprises surveillance cameras, recorders, monitors, lenses, cables, and other electronic accessories.

Costar Technologies provides solutions for financial institutions, educational facilities, retail stores, and manufacturing plants. It also provides solutions for highways, government buildings, military bases, borders, and other applications.

Costar Video Systems is a top provider of electronic security products for the video surveillance market. IVS Imaging is the industrial video division of Costar Video Systems. IVS Imaging distributes video surveillance, industrial video, machine vision and other OEM (original equipment manufacturer) products from the world’s foremost manufacturers.

CohuHD Costar has for more than six decades manufactured electronic security products for the video surveillance market. Costar Technologies has manufacturing capabilities in the United States, China, and Korea.

The Company’s business strategy is to focus on Retail, Financial, Transportation, and Defense markets. Its research and development (R&D) efforts are dedicated to on-board camera analytics. Moreover, its strategy is to add $5-$10 Million of revenue per annum via acquisitions.

Costar Technologies’ business strategy also includes infrastructure improvements. This includes Net Suite Implementation; Supply Chain Improvements; Solution Selling and reducing customer concentration.

Recently, Costar Technologies announced its financial results for Q1 ended March 31, 2018. The Company realized Revenue of $10,917. This represents an increase of $1,346 or 14.1 percent from the quarter ended March 31, 2017.

It realized GAAP Net Income of $50 or $0.03 per share based on 1,589 fully diluted shares outstanding, versus a GAAP Net Loss of ($159) or ($0.11) per share based on 1,493 fully diluted shares for the quarter ended March 31, 2017.

Costar Technologies, Inc. (CSTI), closed Tuesday's trading session at $8.70, down 5.43%, on 455 volume with 4 trades. The average volume for the last 60 days is 819 and the stock's 52-week low/high is $6.01/$11.00.

chart

The QualityStocks Company Corner

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

Over the past few months, PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has been working on the advancement of its innovative Sol-gel drug delivery research program. The focus of the research is to apply Sol-gel technology to develop cannabinoid-based therapies for the relief of symptoms associated with pain, inflammation, seizures and neurological disorders.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0503, up 44.96%, on 17,000 volume with 2 trades. The average volume for the last 60 days is 20,396 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

chart

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

Good tidings continue to grace the lithium industry, the latest being the 2018 report from British minerals analyst Roskill. After a recent market analysis, the British consultancy estimated that lithium demand from automotive applications, which reached over 34,000 metric tons of lithium carbonate equivalent (LCE) in 2017, will more than double by the end of the decade. Some of that demand could be satisfied by QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ).

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.315, up 12.42%, on 34,150 volume with 18 trades. The average volume for the last 60 days is 119,118 and the stock's 52-week low/high is $0.0748/$1.46.

Recent News

chart

Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech (OTC: ETST), an innovative biotech company, is now prototyping three cannabinoid-based (“CBD”) patent formulas. To view the full article, visit: http://cnw.fm/dMA08.

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.80, up 0.80%, on 10,532 volume with 19 trades. The average volume for the last 60 days is 13,094 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria") announces the results of the 2018 Annual General and Special Meeting. All motions were passed. Lexaria thanks its shareholders for their overwhelming support as the Company continues to make significant progress in pursuing its objectives.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $2.00, even for the day, on 45,540 volume with 90 trades. The average volume for the last 60 days is 273,153 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

chart

ChineseInvestors.com (OTCQB: CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

Premier financial information company ChineseInvestors.com, Inc. (OTCQB: CIIX) recently entered a licensing partnership to redistribute popular interviews in the Chinese language. To view the full article, visit: http://cnw.fm/9Fnpy.

Founded in 1999, ChineseInvestors.com (OTCQB: CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.42, even for the day, on 6,701 volume with 8 trades. The average volume for the last 60 days is 53,839 and the stock's 52-week low/high is $0.40/$1.58.

Recent News

chart

Virtual Crypto Technologies Inc. (OTCQB: VRCP)

The QualityStocks Daily Newsletter would like to spotlight Virtual Crypto Technologies Inc. (VRCP).

CryptoNewsAudio announces the Audio Press Release (APR) titled "Cryptocurrency and Blockchain Innovators Poised to Reap Rewards as Fintech Reshapes How Money Is Used," featuring Virtual Crypto Technologies Inc. (OTCQB: VRCP). To hear the CryptoNewsAudio version, visit: http://ccw.fm/lj6iS. To read the original editorial, visit: http://ccw.fm/TVj3b. Also today, NetworkNewsWire released a report on the company detailing how VRCP’s NetoBit platform delivers high accuracy and cuts cryptocurrency transaction time by deploying its predictive algorithm. To view the full article, visit: http://nnw.fm/AtO9H.

Virtual Crypto Technologies Inc. (OTCQB: VRCP) is a developer of software and hardware for the purchase and sale of cryptocurrencies through ATMs, tablets, PCs and mobile devices. The company’s proprietary algorithmic technology trading platform, called NetoBit Trader, can instantaneously confirm the purchase or sale of Bitcoin, a process that typically can take between 10 minutes to 24 hours. All trades and exchanges are insured up to $3,000 per trade. The global cryptocurrency ATM market is predicted to surpass $285 million by 2025, yet, at present, only 30 percent of these machines allow two-way trades.

With NetoBit Trader, cryptocurrency holders enjoy immediate confirmation of Bitcoin and its crypto equivalents at the best crypto exchange rate at the point of transaction – providing a major breakthrough in the quest to bring cryptocurrencies to the mass market. Virtual Crypto’s cryptocurrency ATM, embedded with currency exchange transaction validation (CETV) in its hardware and software, accepts and dispenses cash and cryptocurrency in seconds.

Virtual Crypto’s NetoBit Trader and mobile retail point-of-sale platform incorporates advanced technologies tailored to the needs of primary market players, users, investors, and business owners. Virtual Crypto’s platform bridges the three main functions of the cryptocurrency sector – exchanges, wallets and payments – to the world of fiat exchanges, granting access to immediate cash exchanges between consumers and businesses worldwide.

NetoBit Trader’s over-the-counter, two-way transaction solution is available through one app, providing online cryptocurrency transactions at ecommerce and gaming portals. The app provides real-time cryptocurrency validation and exchange, easy buying and selling of Bitcoin with cash, enables traders to buy and trade crypto, and gamers to transfer cryptocurrency into cash after play. Crypto users can withdraw funds from their crypto accounts through a NetoBit cryptocurrency ATM or software-enabled tablet, and consumers can purchase retail with crypto from businesses that offer and use the NetoBit software.

The company’s newly redesigned corporate website, www.virtual-crypto.com, delivers a simple, clean design with enhanced functionality, features and navigation. Virtual Crypto’s new corporate website includes:

  • Downloadable NetoBit Trader app link and contact forms for more information
  • MarketWatch provides real-time tracking of the Bitcoin market, with other currencies to follow
  • Improved security utilizing https certificates to protect personal information and site integrity
  • Media room with downloadable product brochures, corporate presentations and other relevant content
  • Investor’s page provides transparency to investors with direct access to Virtual Crypto’s progress through press releases, SEC filings, senior management team bios, and stock performance charts
  • Social Media integration with buttons for LinkedIn, Twitter and Facebook jump to Virtual Crypto’s social media profiles, providing real-time updates from the online community

“Our primary objective is to make cryptocurrencies accessible to everyone, and that was the motivation for our redesign,” said Alon Dayan, Chief Executive Officer of Virtual Crypto. “The updated content provides real value for our customers, shareholders and employees, showcasing our products and services, in an intuitive, easy to navigate way.”

Virtual Crypto’s strategic vision of “Cryptocurrency Made Easy” allows crypto traders and users to overcome the complex hurdles currently hampering the cryptocurrency sphere.

Virtual Crypto Technologies Inc. (VRCP), closed the day's trading session at $0.14, even for the day, on 7,000 volume with 2 trades. The average volume for the last 60 days is 37,068 and the stock's 52-week low/high is $0.0125/$0.38.

Recent News

chart

DeepMarkit Inc. (TSX-V: MKT) (OTCQB: MKTDF)

The QualityStocks Daily Newsletter would like to spotlight DeepMarkit Inc. (MKTDF).

Less than four months after launching its slide-out app “Gamify” for e-commerce websites, DeepMarkit Inc. (TSX.V: MKT) (OTCQB: MKTDF) announced that it has achieved an average of 61 percent month-over-month growth in its merchant base. Positive customer feedback and the onboarding of hundreds of new customers each month continues to energize DeepMarkit’s development team to create new features for its popular app.

DeepMarkit Inc. (TSX-V: MKT) (OTCQB: MKTDF), based in Calgary, Alberta, Canada, is a patent pending gamification technology company inventing new ways to engage consumers and other audiences. The Company’s proprietary promotions platform – “Gamify” – enables businesses and agencies to create branded games that incentivize consumers, thus driving sales, capturing data and generating leads. The DeepMarkit platform integrates next-gen gamification engagement mechanics with interactive advertising industry standards and powerful visuals, including 3-D images. Customers may choose from both free and paid solutions suitable for campaigns of all sizes, targeting multiple channels on the web, mobile and social media.

A team of seasoned, passionate gaming executives, led by president and CEO Darold Parken, has worked together for more than 15 years developing games and gaming systems that are still used today by some of the largest gaming companies in the world. This accomplished executive team founded Chartwell Technologies, acquired in 2011 by Amaya Gaming, which now is known as The Stars Group (Nasdaq: TSG) with a market cap of over $5 billion.

Gamify offers a selection of easily customizable gaming apps featuring a customer’s branded e-store in addition to tailored landing pages, technical support, real-time analytics, data collection and an engaging marketing campaign. Gamify’s patent-pending app comes complete with unique user incentives that draw consumers in with games and prizes, which in turn engages shoppers, turning them into buyers and building brand loyalty.

The gamification market is rapidly expanding and projected to be worth $22 billion by 2022, with a CAGR of 41 percent. DeepMarkit is the only publicly listed company focused solely on this exploding market that embraces any size of business, from the mom-and-pop shops to the blue-chip giants. DeepMarkit’s management team knows that increasing a customer’s conversion rate by a mere 1 percent has the potential to double revenue, which is why Gamify’s app and its ability to transform simple shoppers into engaged buyers is so compelling.

“Our marketing platform enables customers to build branded games that incentivize audiences, generate leads, and drive sales. Businesses need a way to stand out from the crowd,” Parken states in an investor’s video (https://www.youtube.com/watch?v=97hJoRKR92k). “DeepMarkit’s gamification platform gives customers that way to stand out and it’s a way that they can afford. That’s the strength of our platform. For a relatively small amount of money, any business can create a very powerful, high quality customer engagement using gamification.”

DeepMarkit recently entered into a joint marketing agreement with ITN International (“ITN”), a global leader in trade show data capture and analytics. The agreement will enable the 1.5 million exhibitors at the 125-plus yearly events serviced by ITN to purchase a customizable campaign with prize delivery and branded games that can be used in collaboration with ITN’s lead retrieval solutions. DeepMarkit and ITN are currently integrating DeepMarkit’s patent-pending gamification platform directly into ITN’s exhibitor portal.

“We started DeepMarkit because we have a passion for games and we believe in the power of games, not just for entertainment but more importantly as a tool for business,” Parken said. “DeepMarkit is a gamification company. What we mean by that is that we create innovative ways to use games for business purposes. Games to generate customer leads, games to promote products, deliver rewards, build brand awareness and customer loyalty.”

Selected as the winner of the New Company/Product pitch competition at the Retail Global 2017 Conference held in Las Vegas, Gamify’s platform has also attracted a $1.5 million investment from Allstate International LLC in Hong Kong. The investment gives Allstate a 10 percent stake in DeepMarkit and a great opportunity to bring the Gamify platform into the burgeoning Asian gaming market.

DeepMarkit Inc. (MKTDF), closed the day's trading session at $0.0364, even for the day. The average volume for the last 60 days is 37,389 and the stock's 52-week low/high is $0.0293/$0.12.

Recent News

chart

Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (OTC: MCOA) is uniquely positioned to capture a substantial share of the industrial hemp market, offering increased value for its shareholders. To view the full article, visit: http://cnw.fm/HD0sa.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0353, off by 11.53%, on 10,585,963 volume with 270 trades. The average volume for the last 60 days is 7,303,573 and the stock's 52-week low/high is $0.0195/$0.0728.

Recent News

chart

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF) (“FinCanna”) a royalty company for the U.S. licensed medical cannabis industry, announces that it has closed its oversubscribed private placement previously announced on June 15 and upsized on June 18, 27 and 29, 2018.  The Company issued 20,396,535 Units at a price of $0.30 per unit for gross proceeds of $6,118,961. The Company anticipates some additional funds to be received within the week and will close these additional units at that time.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.2259, off by 15.87%, on 127,044 volume with 43 trades. The average volume for the last 60 days is 38,893 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

chart

Zenosense, Inc. (OTC: ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the point-of-care (“POC”). To view the full article, visit: http://nnw.fm/2fgYF.

Zenosense, Inc. (OTC: ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.40, off by 2.44%, on 195,993 volume with 47 trades. The average volume for the last 60 days is 265,141 and the stock's 52-week low/high is $0.15/$0.895.

Recent News

chart

GTX Corp. (OTC: GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO).

GTX Corp. (OTC: GTXO) designs, manufactures and commercializes various products and services in the GPS tracking and monitoring business.  Operating domestically and internationally, via two subsidiaries engaged in the internet of things (IoT) and wearable technology industry. Founded in 2002 and headquartered in Los Angeles, California, the company is a pioneer in Smart GPS, cellular and Bluetooth Low Energy (BLE) tracking technology, offering complete, end-to-end tracking solutions through a proprietary IoT enterprise monitoring platform – the IoT Machine to Machine platform – backed by state-of-the-art hardware, software and connectivity solutions, patents and software algorithms.

Operating under the motto “We Put the ‘Where’ in Wearable Tech,” GTX’s main goal is to keep its customers connected to who and what matters most, with each of its patented tracking technologies providing real-time location coordinates on a map via a personalized portal. The company prides itself on offering not only technologies, but also effective solutions that provide safety, security and peace of mind by helping customers locate their loved ones or lost valuable items.

With a portfolio that includes more than 80 patents filed and issued and with products and services available in 35 countries, GTX’s tracking solutions use the latest in miniaturized, low-power GPS, mobile, RF and BLE technology, that can integrate seamlessly with multiple consumer products, enterprise and military applications. The company became a U.S. Military contractor in 2017 and is already developing asset and human tracking technology for the U.S. Air Force. Its list of customers also includes public health authorities and municipalities, emergency and law enforcement, NGOs, private companies, public and private senior care homes, and consumers.

The company’s flagship product is the award-winning GPS SmartSole®, the world’s first invisible wearable tracking device created specifically for people at risk of wandering, becoming lost or disoriented, including patients with Alzheimer’s, autism, dementia, traumatic brain injury and other cognitive problems. According to the World Alzheimer Report 2013 (http://nnw.fm/mrcV2), there are more than 100 million people worldwide who need constant care and monitoring because of a cognitive disorder, and their number is expected to rise to 277 million by 2050. Due to its hidden location – inside a shoe insert, the device can also be used by people undercover or at risk of kidnapping, such as government agents, military personnel, law enforcement, journalists, corporate executives, etc.

Other tracking devices designed and commercialized by the company for civilian or military use include:

  • Take-Along Tracker 3G: A powerful mini-tracking device with GPS, 2G and 3G GSM data and voice capabilities, as well as a motion sensor and sleep mode. The device can be easily attached to a keychain, lanyard, dog collar, pocket, bag or plush toy for a discreet but advanced tracking solution.
  • Invisabelt: Designed for children, this slim GPS tracker hidden inside a small waistband belt has a battery life of up to two days and is a great solution for parents who want to monitor their children’s location at all times.
  • Track My Workforce: An easy and cost-effective solution that allows businesses to track and monitor their mobile workforce. The app is available for both Android and iOS systems, and allows employers to monitor their workforce from a single company account.
  • E.T.S. -Personnel Equipment Tracking System: Currently in use at the Edwards Air Force Base, this tracking system allows real-time monitoring and surveillance of personnel and assets and has a 200+ square mile coverage. Solar powering capabilities and extend battery life allow the tracker to be used in areas without existing power sources.
  • GPS Rifle Tracker: The company’s smallest GPS tracker, designed to withstand shocks and water submersion due to its robust, military standard enclosure, can be mounted on any AR15 platform picatinny rail to detect weapon discharge, track weapons and inventory, and send time and location alerts.

Led by a management team with solid experience in wearable technology, IoT, consumer electronics, mobile and technology licensing, as well as finance and the footwear industry, GTX plans to leverage its core technology platform to reach new verticals via licensing agreements and strategic partnerships, and to monetize its intellectual property portfolio. The monetization campaign kicked off in 2017 has already identified 100 companies that could become licensees. Besides military and law enforcement, the company also eyes the biometrics market, home health, medicare and insurance and other security applications for potential uses of its IoT platform and tracking technology.

GTX currently has 15 domestic and international distributors, subscribers in 35 countries and more than 700 online affiliates. With multiple revenue streams, several consecutive years of double-digit revenue growth and a strong pipeline of lucrative commercial products, GTX is uniquely positioned to become a leading provider of tracking solutions on this growing multi-billion-dollar market.

GTX Corp. (GTXO), closed the day's trading session at $0.0019, up 18.75%, on 718,968 volume with 12 trades. The average volume for the last 60 days is 5,405,724 and the stock's 52-week low/high is $0.0011/$0.0089.

Recent News

chart

NUGL Inc. (OTC: NUGL)

The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (OTC: NUGL), is a search engine and online directory for the marijuana industry. NUGL’s database includes listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands. The company focuses on leading the evolution in business relations, development and organic data in the cannabis industry with metasearch technology.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.12, up 0.90%, on 44,633 volume with 56 trades. The average volume for the last 60 days is 93,644 and the stock's 52-week low/high is $0.405/$1.80.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.